Customize your JAMA Network experience by selecting one or more topics from the list below.
Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
The immune system helps protect the body from infection and other diseases, including cancer.
Immune checkpoint inhibitors are cancer treatment drugs that prevent immune cells from being turned off by cancer cells.
During an immune response, the immune system turns on to attack potentially harmful agents. The immune system also has ways to turn off. This limits the immune response and prevents damage to healthy tissues.
T lymphocytes,or T cells, are immune system cells that can kill cancer cells. A T cell has special locations on its surface called receptors. Other cells or molecules attach to these receptors and turn the T cell on (activation) or off.
Some cancer cells bind to receptors on activated T cells and turn them off. Immune checkpoint inhibitors are drugs that prevent cancer cells from turning off T cells. This allows T cells to infiltrate a tumor and stop it from growing.
Conventional chemotherapy drugs often shrink a tumor within weeks, but immune checkpoint inhibitors can take several months to work. These drugs can initially cause the tumor to swell, making it appear that the tumor is growing. This is called pseudoprogression. It occurs because of the large number of activated T cells and other immune system cells and substances that enter the tumor. The brief increase in tumor size may be followed by shrinking or eradication of the tumor.
The US Food and Drug Administration has approved several immune checkpoint inhibitors for the treatment of metastatic melanoma. These approved drugs include ipilimumab (Yervoy; Bristol-Myers Squibb), nivolumab (Opdivo; Bristol-Myers Squibb), and pembrolizumab (Keytruda; Merck Sharp & Dohme Corp). These drugs are also being tested for treatment of many other cancers.
Because immune checkpoint inhibitors prevent T cells from being turned off, these drugs affect the balance of the immune system. In addition to infiltrating tumors, activated T cells can attack the body’s own cells. This is called an autoimmune reaction and occurs in about 10% of patients taking these drugs.
Immune-related side effects usually occur 6 to 12 weeks after starting treatment and may include
Yellowing of the skin (jaundice)
Change in energy level
Be sure to let your doctor know if you develop any new symptoms while taking an immune checkpoint inhibitor. Your doctor might temporarily stop the drug or prescribe a steroid to decrease the immune response.
Immunotherapy Patient Forumhttp://cancergrace.org/cancer-treatments/immunotherapy-patient-forum-2014-videos/
To find this and other JAMA OncologyPatient Pages, go to the Patient Page link on the JAMA Oncology website at http://www.jamaoncology.com.
Published Online: March 5, 2015. doi:10.1001/jamaoncol.2015.0137.
Conflict of Interest Disclosures: None reported.
West H. Immune Checkpoint Inhibitors. JAMA Oncol. 2015;1(1):115. doi:10.1001/jamaoncol.2015.0137
Create a personal account or sign in to: